GlaxoSmithKline, which filled the seat of CEO-bound Emma Walmsley on Thursday, isn’t the only Big Pharma to tap a new consumer chief this week.
On Friday, rival Sanofi announced it had appointed Alan Main to lead its OTC efforts, which will take the form of a newly created consumer health global business unit.
It’s a poach job by new Sanofi CEO Olivier Brandicourt, who recruited Main from his former employer, Bayer. At the German drugmaker, Main served as global president of medical care, but he has plenty of consumer experience from his pre-Bayer days at Roche Consumer Health, a business Bayer picked up in 2004.
Now, he’ll be tasked with leading a newly bulked-up business in an increasingly competitive space. Sanofi is currently working to close an asset swap for Boehringer Ingelheim’s consumer portfolio–for which it traded away its animal health offerings–and it expects to do so by the end of this year. Once it does, it’ll become a leader in the OTC field, it figures–meeting one of the key goals it laid out in its “roadmap 2020.”
Of course, Sanofi isn’t the only player fighting to gain ground in the consumer health arena. GlaxoSmithKline, which took the lead after starting up a JV with Novartis early last year, intends to keep the top spot, and it Thursday announced that Novartis vet Brian McNamara would be leading that charge as head of the venture.
Bayer, too, has said it’s gunning for the worldwide No. 1 position in the OTC market, though lately it’s focused its energies elsewhere. Earlier this month, it agreed to shell out $66 billion on agricultural giant Monsanto, a deal some industry watchers worry will hurt its pharma ambitions.
By Carly Helfand
Source: Fierce Pharma
As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.
McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.
AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.